SC0062
Diabetic Kidney Disease (DKD) with Albuminuria
Phase 2Breakthrough Therapy Designation in China (June 2025)
Key Facts
Indication
Diabetic Kidney Disease (DKD) with Albuminuria
Phase
Phase 2
Status
Breakthrough Therapy Designation in China (June 2025)
Company
About BioCity Biopharma
A clinical-stage biopharma developing novel BIC/FIC therapeutics for oncology and nephrology, with a multi-modality pipeline and global clinical operations.
View full company profileAbout BioCity Biopharma
A clinical-stage biopharma developing novel BIC/FIC therapeutics for oncology and nephrology, with a multi-modality pipeline and global clinical operations.
View full company profile